AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.31 USD | -0.80% | +2.25% | +509.56% |
Apr. 02 | North American Morning Briefing : Stocks Seen -2- | DJ |
Apr. 01 | HC Wainwright Downgrades Landos Biopharma to Neutral From Buy | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
159.6 USD | -4.58% | -4.08% | 283B | ||
22.31 USD | -0.80% | +2.25% | 69.53M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+509.56% | 69.53M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- LABP Stock
- News Landos Biopharma, Inc.
- AbbVie Inc. agreed to acquire Landos Biopharma, Inc. on March 24, 2024.